A carregar...
LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood p...
Na minha lista:
| Publicado no: | J Clin Hypertens (Greenwich) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8032009/ https://ncbi.nlm.nih.gov/pubmed/26402918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12667 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|